Clinical Efficacy of Arsenic Trioxide Combined with Chemotherapy in the Treatment of Acute Myeloid Leukemia

Objective To evaluate myeleid leukemia the clinical value and effect of arsenic trioxide combined with chemotherapy in patients. Methods A total of 52 patients with acute myeloid leukemia admitted to our hospital from September 2017 to September 2018 were selected. By lottery grouping, they were divided into two grouops, with 26 cases in each group. Conventional therapy was used in the control group. And arsenic trioxide combined with chemotherapy was used in the observation group. Effective treatment of statistical values, bone marrow suppression, and adverse reaction statistics were recorded and compared. Results The effective treatment statistics(88.46%) of the patients with acute myeloid leukemia were higher than those of the control group(61.53%), and the difference was statistically significant(χ2=5.025 6, P=0.024 9<0.05). The statistical value of adverse reactions in patients with acute myeloid leukemia in the observation group(15.38%) was lower than that in the control group(42.30%), and the difference was statistically significant(χ2=4.591 0, P=0.032 1<0.05);after treatment,the acute myeloid in the observation group Leukemia patients with white blood cell counts(0.55 ± 0.11)×10^9/L, platelet values(25.65±0.36)×10^9/L, CD34+(2.56±0.01), P-gp(10.21±0.24)% better than the control data [(0.69±0.11)×10^9/L,(30.54±0.37)×10^9/L,(4.54±0.33)%,(18.51±0.57)%], the difference was statistically significant(P<0.05);the survival time of patients with acute myeloid leukemia in the observation group(12.32±0.21) months were longer than the control group(6.52±2.00)months, and the difference was statistically significant(t=14.706 3, P=0.000 0<0.05). Conclusion For acute myeloid leukemia patients, arsenic trioxide combined with chemotherapy can improve white blood cell count, platelet value, CD34+, P-gp, and reduce adverse reactions.